Synthetic Biology Accounting: Assessing Financial Implications of Gene Editing and
DNA Synthesis
Introduction
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
Synthetic biology represents a new frontier of scientific advancement with the potential for
revolutionary innovations across many fields. By allowing for customized manipulation and
engineering of biological systems at the genetic level, synthetic biology enables targeted
modifications and applications not otherwise possible. With its promise also comes
responsibility, as gene drives, gene therapies, and other synthetic products bring new
financial and ethical considerations. As synthetic biology matures and its applications
diversify, accounting standards must evolve to ensure risks and impacts are properly
understood and accounted for.
This paper will explore the key financial implications of gene editing and DNA synthesis
associated with synthetic biology and propose an accounting framework for systematically
assessing these implications. The first section provides background on recent advances in
gene editing and DNA synthesis empowering synthetic biology applications. The next section
analyzes financial implications including research and development costs, product
commercialization pathways, insurance and liability considerations, valuation challenges, and
regulations. After synthesizing these factors, a section proposes high-level accounting
principles and standards for systematically incorporating synthetic biology's financial
implications into company and project evaluations. The conclusion discusses remaining open
questions and opportunities for the accounting profession to create transparency and support
responsible innovation in synthetic biology.
Advances in Gene Editing and DNA Synthesis
Rapid advances in gene editing and DNA synthesis underpin the emergence of synthetic
biology. CRISPR-Cas9 gene editing has allowed for precise and inexpensive manipulation of
DNA in living cells and organisms. Other techniques like TALENs and zinc finger nucleases
also enable cutting at targeted DNA locations. DNA synthesis has advanced from individual
genes to now being able to synthesize entire bacterial genomes from digitally defined DNA
sequences. These advances empower targeted changes to genomes including editing,
deleting, adding or modifying genes.
Major gene editing and DNA synthesis milestones of the past decade include:
- 2012: First use of CRISPR-Cas9 for gene editing in mammalian cells [1]. Its simplicity and
precision compared to preceding techniques has made it the dominant tool for synthetic
biology applications.
- 2013: First synthetic bacterial genome transplanted into live bacterial cell [2]. Demonstrated
capabilities for complete redesign of genomes outside of regulatory and genetic constraints.
- 2015: CRISPR used to edit specific genes in non-viable human embryos for first time [3].
Highlighted potential for germline gene editing while also sparking significant ethical
debates.
- 2016: DNA synthesis company synthesized ~1.1 million base pair yeast genome, the largest
synthetic genome yet [4]. Underscored rapid DNA assembly capabilities now possible at
industrial scales.
- 2018: First approved use of CRISPR to edit human T-cells ex vivo to potentially treat
cancer [5]. Represented important milestone for clinical translation of gene therapies.
- 2020: De novo synthesis of SARS-CoV-2 virus genome sequence to better study the
pandemic coronavirus in the lab [6]. Demonstrated both risks and benefits arising from DNA
synthesis capabilities.
These technical advancements have allowed targeted changes inaccessible just a decade ago
and enabled new applications across agriculture, biomanufacturing, medicine, and more.
However, their financial implications are still emerging and require a framework for
systematic accounting.
Financial Implications of Synthetic Biology
Gene editing and DNA synthesis applied through synthetic biology introduce both financial
opportunities and risks with implications for assessing projects, valuing companies, and
managing liabilities. Key financial factors associated with these technologies include:
Research and Development Costs
Development of new gene editing and DNA synthesis capabilities as well as resulting
synthetic biology applications involve substantial research and development (R&D)
expenditures. Single CRISPR clinical gene therapy trials have spent over $10 million on
R&D costs alone [8]. DNA synthesis of genomes also remains expensive, with costs scaling
approximately linearly with DNA length [9]. As new techniques and programs are developed,
accounting must reliably track such multifaceted R&D costs against projected value to assess
viability.
Commercialization Pathways
Financial outcomes depend strongly on how synthetic biology applications pursue regulatory
approval and commercialization pathways. Gene therapies navigating lengthy clinical trials
for FDA approval differ vastly from field tests of gene drive modified crops. Costs, timelines
and revenues differ between pharmaceutical, agricultural, industrial, and research
applications [10]. Accounting must incorporate implications of specific commercialization
strategies and uncertainty.
Valuation Challenges
In early stages, synthetic biology companies developing new techniques or applications face
difficulties in valuation. Unlike drugs with projected sales curves, financial value relies more
on intellectual property, platform technologies, and future licensing agreements [11].
Contingent value methods may be needed to assess startups where near-term profits are
unclear [12]. Standardization could help address these challenges.
Insurance and Liability
Unanticipated consequences of gene drives, gene therapies, or synthetic organisms pose risks
of environmental, health or economic damages with liability costs [13]. As use scales,
significant insurance expenditures may be required, and accounting must provision for such
contingencies [14]. Regulations may also introduce new compliance costs that impact
viability assessments [15]. Long-term monitoring programs post-release further introduce
costs.
Regulatory Compliance and Policy Changes
Regulations governing research, field testing and commercialization of gene drives, genetic
engineering of food crops or clinical gene therapies impact financial outcomes [16]. Evolving
regulatory landscapes introduce uncertainty requiring scenario analysis. Sudden policy
changes could invalidate R&D efforts or necessitate expensive retrofits [17]. Proper
accounting informs regulatory engagement and policy discussions.
Incorporating these diverse financial implications systematically into company and project
evaluations through accounting standards supports responsible development of synthetic
biology. The following section proposes accounting principles for this emerging field.
Proposed Accounting Principles for Synthetic Biology
Given synthetic biology's diverse financial considerations, this section proposes overarching
accounting principles and guidelines for systematically incorporating key implications:
1. Multidimensional Research and Development Accounting
- Track multifaceted R&D costs separately for new techniques, safety testing,
commercialization strategies to reliably estimate total expenditures against projected value at
key stages.
- Incorporate uncertainty through scenario-based modeling of alternate pathways (clinical
trials vs. environmental releases vs. strategic partnerships etc.) with sensitivity analyses.
2. Contingent Liabilities Accounting
- Make provision for contingent liabilities from potential environmental damages,
unintended effects, legal challenges or fines from non-compliance through insurance
estimates and financial contingencies.
- Require assessments of escalating insurance costs as scale increases and quantify
provisions under alternative risk scenarios.
3. Intellectual Property and Valuation Standards
- For early-stage companies, establish protocols valuing proprietary techniques, patent
portfolios, IP ownership as intangible assets contingent on future agreements and milestones.
- Mandate discounted contingent value assessments under alternative partnership and
licensing scenarios.
4. Disclosure of Regulatory Compliance Costs
- Quantify expenditures associated with evolving regulations at discovery, field testing and
commercialization stages including scenarios of stricter future requirements.
- Highlight compliance as a material uncertainty and monitor impacts of policy changes on
long term viability.
5. Long-Term Monitoring Program Accounting
- Include costs of multi-year monitoring programs post-environmental release or clinical
use under provisions for product lifecycle management.
- As long term fiscal impacts may not be quantifiable ex-ante, outline management
protocols for unforeseen future costs.
6. Scenario Planning and Sensitivity Analysis
- Require predictive modeling that incorporates parameters such as R&D uncertainty,
regulatory trajectories, insurance costs, partnership variables, and liability risks under a range
of plausible scenarios.
- Conduct sensitivity analyses altering key assumptions to understand project resilience to
unexpected variations.
7. Periodic Reappraisal
- Mandate reappraisal of accounting values and viability assessments at predefined project
stages or when circumstances indicate re-evaluation is prudent given fast-changing
technological and regulatory landscapes in synthetic biology.
By adopting such principles, accounting can systematically factor in diverse long term
uncertainties and contingencies integral to synthetic biology. Proper due diligence ensures
transparent and responsible development aligned with societal priorities. Evolving metrics
with the field supports continued responsible innovation.
Conclusion
Synthetic biology promises revolutionary innovations but also introduces unprecedented
implications. As its applications diversify, accounting standards must evolve
commensurately. This paper has analyzed diverse financial factors like costs, risks and
uncertainties arising specifically from gene editing and DNA synthesis. By synthesizing
these, it proposes high-level accounting principles for systematically assessing synthetic
biology projects and valuing associated companies.
Open questions remain regarding quantification of long term contingencies, valuation under
deep uncertainty, and responsible allocation of provisions. The accounting profession has an
opportunity to create needed transparency through engagement with synthetic biologists and
oversight bodies. Standardization supports decision makers while flexible scenario-based
approaches accommodate rapid advancement. Overall, a prudent, scenario-based accounting
framework can balance innovation and oversight—enabling synthetic biology's benefits while
guiding its maturation along socially acceptable trajectories. With responsible due diligence
and periodic re-evaluation, accounting can help maximize synthetic biology's promise
responsibly.
